Jeremy Bender

Money Moves

Leading Day One through Servier acquisition

For decades, children with relapsed brain tumors had no approved targeted treatment. That changed in April 2024 when the FDA cleared Ojemda, a once-weekly pill for pediatric low-grade glioma, the most common childhood brain cancer. Day One Biopharmaceuticals, the company behind it, has agreed to be acquired by France's Servier for $2.5 billion in cash—a 68% premium over its previous closing share price.

Updated May 30